Medisys rejigs senior team ahead of change in focus
This article was originally published in Clinica
Executive Summary
UK syringe and glucose monitoring unit producer Medisys has elevated chief operating officer David Conn to the position of CEO, ahead of the company's planned transition from a product development business to a diversified medical devices company. His appointment, and two associated changes to the composition of the senior management, are designed to help the company maximise the commercial potential of products that are on the point of launch in the US.
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.